Literature DB >> 1582300

Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo.

F P Maesen1, R Costongs, S J Smeets, P G Zweers, D M Goedhart.   

Abstract

We compared the bronchodilator effects and systemic tolerability of 12, 24 and 48 micrograms formoterol DP capsules with 12 micrograms formoterol MDI and placebo in 30 patients with reversible obstructive airway disease. Pulmonary function tests were done and pulse rate and blood pressure were recorded. We observed significant differences between all active substances vs placebo regarding peak effect, duration of effect and AUC value. No significant difference was observed between either 12 or 24 micrograms formoterol DP and 12 micrograms from MDI in all mentioned parameters. With 48 micrograms DP, increased peak effect, AUC and duration of effect were noted. Heart rate Holter monitoring showed a slightly more pronounced effect with 48 micrograms. We conclude that 12 to 24 micrograms formoterol DP capsules are equivalent to 12 micrograms of formoterol MDI regarding efficacy and tolerability, while 48 micrograms formoterol DP capsules cause more profound effects in bronchodilation and on the heart rate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582300     DOI: 10.1378/chest.101.5.1376

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

Review 1.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 2.  Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.

Authors:  R A Bartow; R N Brogden
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 3.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.

Authors:  Katayoon Najafizadeh; Hamid Sohrab Pour; Mojtaba Ghadyanee; Masoud Shiehmorteza; Masoud Jamali; Sayeed Majdzadeh
Journal:  Emerg Med J       Date:  2007-05       Impact factor: 2.740

Review 5.  Regular treatment with formoterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.